Execution of the Fourth Medium-Term Management Plan
First written in FY2016. 3 of 9 entries say "Reframed", first in FY2018. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026ReframedAnnual report
「The Group is working on the long-term vision “Machi no Akari Vision 2035” and the Seventh Medium-Term Management Plan based on that vision, covering the fiscal years ending March 2027 through March 2030.」
After the period covered by the Sixth Medium-Term Management Plan ended, the company shifted to a new planning framework centred on the long-term vision and the Seventh Medium-Term Management Plan. - FY2025SoftenedAnnual report
「The company formulated the “Sixth Medium-Term Management Plan” and promoted further expansion of an integrated platform combining the Group’s community pharmacies and pharmaceutical network members, the provision of high-quality healthcare and services, the rationalisation of the pharmaceutical distribution market, and expansion of the pharmacy support business, comprising the pharmaceutical network business, pharmaceutical manufacturing and marketing business, and digital shift business. However, achieving the medium-term plan has become difficult due to changes in the business environment, including delays in launching new revenue businesses, front-loaded costs for developing new businesses and stores, higher pharmaceutical procurement prices and increased labour costs resulting from wage increases.」
The company explicitly stated that achieving the Sixth Medium-Term Management Plan had become difficult due to multiple changes in the business environment, among other factors, and execution of the plan’s themes weakened. - FY2025-H1AdvancedAnnual report
「As of 30 September 2024, the company had 452 community pharmacies, 1 care plan centre and 9 cosmetics and drugstores. As of 30 September 2024, the number of pharmaceutical network members totaled 10,435, comprising 452 Group members and 9,983 general members, an increase of 679 from the end of the previous consolidated fiscal year.」
Progress toward the Sixth Medium-Term Management Plan’s final-year targets of 12,000 pharmaceutical network members and 550 community pharmacies reached 10,435 members and 452 community pharmacies. - FY2022ReframedAnnual report
「The company formulated the “Sixth Medium-Term Management Plan” covering the 4 years from April 2022. The following targets have been set for the fiscal year ending March 2026, the final year of the Sixth Medium-Term Management Plan: consolidated net sales of ¥140.0 billion; consolidated operating profit of ¥6.5 billion; operating margin of 4.6%; consolidated EBITDA of ¥10.0 billion; 12,000 pharmaceutical network members; 550 directly operated community pharmacies; and an equity ratio of 30.0%.」
The company shifted from the Fifth Medium-Term Management Plan to the Sixth Medium-Term Management Plan and set targets for net sales, profit, membership, store count and the equity ratio for the fiscal year ending March 2026. In the pharmacy support business, it also aims to increase profit by more than ¥3.0 billion. - FY2019RaisedAnnual report
「In the pharmaceutical and related network business, while promoting efforts to improve distribution efficiency together with member stores and build local networks linking member stores, the company aims to reach 5,000 members as of the end of March 2020, bringing forward by 2 years the target for the final year of the Fifth Medium-Term Management Plan, the fiscal year ending March 2022.」
The company indicated that it aims to reach the Fifth Medium-Term Management Plan’s final-year target of 5,000 members by the end of March 2020, bringing the target forward by 2 years from the fiscal year ending March 2022. - FY2018ReframedAnnual report
「Under the “Fifth Medium-Term Management Plan,” announced on 8 May 2018 and covering the 4 years from April 2018, the company has set the following targets for the final year, the fiscal year ending March 2022.」
After the period covered by the Fourth Medium-Term Management Plan ended, the planning theme shifted to the Fifth Medium-Term Management Plan starting in April 2018. Under the Fourth Plan, the number of pharmaceutical network members exceeded the target of 2,200, while net sales were ¥93.977 billion and operating profit was ¥3.163 billion. - FY2017SoftenedAnnual report
「Under the Fourth Medium-Term Management Plan, the Group had set targets for consolidated net sales of ¥105.0 billion and consolidated ordinary profit of ¥3.8 billion for the fiscal year ending March 2018. However, due to the impact of the April 2016 revisions to drug prices and dispensing fees, among other factors, the consolidated forecasts for the fiscal year ending March 2018 are net sales of ¥95.0 billion, operating profit of ¥3.1 billion, ordinary profit of ¥3.0 billion and profit attributable to owners of the parent of ¥1.0 billion.」
The Fourth Medium-Term Management Plan remains in effect, but the net sales and profit targets for the fiscal year ending March 2018 have been lowered from the original plan in response to the revisions to drug prices and dispensing fees, among other factors. - FY2017-Q1AdvancedAnnual report
「Performance is progressing ahead of plan.」
The company explained that first-quarter performance was progressing ahead of plan. It did not provide the achievement status of the 7 individual initiatives. - FY2016First statedAnnual report
「The Group will continue to work together on the following 7 priority initiatives under the “Fourth Medium-Term Management Plan,” announced on 1 May 2015 and covering the 3 years from the fiscal year ending March 2016 through the fiscal year ending March 2018」
The company has set out 7 priority initiatives under a 3-year plan covering the fiscal years from March 2016 through March 2018.